Evidence map›Paper›PMID 38224347›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

Characterization of hERG K

Denis V Abramochkin, Oksana B Pustovit, Nikolay Yu Mironov, Tatiana S Filatova, Tatiana Nesterova

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06540352 (A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06540352 phase2active not recruitingnot on this map

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg (Pharmproekt JSC) for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form

TypeinterventionalSponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian FederationRan2024 to 2026Enrolled175ConditionsAtrial Fibrillation, Atrial FlutterArms4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride, Mannitol
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Denis V AbramochkinDepartment of Human and Animal Physiology, Biological Faculty, Lomonosov Moscow State University, Leninskiye Gory, 1, 12, Moscow, Russia. abram340@mail.ru.
Oksana B PustovitDepartment of Human and Animal Physiology, Biological Faculty, Lomonosov Moscow State University, Leninskiye Gory, 1, 12, Moscow, Russia.
Nikolay Yu MironovChazov National Medical Research Center for Cardiology, Moscow, Russia.
Tatiana S FilatovaDepartment of Human and Animal Physiology, Biological Faculty, Lomonosov Moscow State University, Leninskiye Gory, 1, 12, Moscow, Russia.
Tatiana NesterovaInstitute of Immunology and Physiology, Ural Branch of Russian Academy of Sciences, 620049, Ekaterinburg, Russia.

Funding

Ministry of Healthcare of the Russian Federation 1220203000201-5
6 · The paper itself

Abstract

Cavutilide (niferidil, refralon) is a new class III antiarrhythmic drug which effectively terminates persistent atrial fibrillation (AF; 84.6% of patients, mean AF duration 3 months) and demonstrates low risk of torsade de pointes (1.7%). ERG channels of rapid delayed rectifier current(I

Indexed as

Anti-Arrhythmia AgentsERG1 Potassium ChannelAnimalsCHO CellsCricetinaeCricetulusEther-A-Go-Go Potassium ChannelsHumansPatch-Clamp TechniquesPhenethylaminesPiperidinesPotassium Channel BlockersSulfonamidesAnti-Arrhythmia AgentsdofetilideERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsniferidilPhenethylaminesPiperidinesPotassium Channel BlockersSulfonamidesAntiarrhythmic drugAtrial fibrillationDelayed rectifier – CavutilideIonic currentsPatch-clamp

Identifiers

PMID38224347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.